Kestra Private Wealth Services Increases Stake in Chemomab Therapeutics Stock
What happened
Kestra Private Wealth Services LLC increased its institutional stake in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) on October 12, 2026. This increase was tracked through a filing with the Securities and Exchange Commission. Chemomab Therapeutics recently reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.12).
From themarketsdaily.com
Why it matters
The increase in institutional holdings by Kestra Private Wealth Services LLC suggests a shift in investor confidence in Chemomab Therapeutics. The company saw a decline of 87.1% in short interest between September 15th and September 30th.
From themarketsdaily.com
Who's involved
- Securities and Exchange CommissionGovernment agency that oversees mandatory regulatory filings
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- FDRSpeculative
The increased institutional demand could potentially affect the stock price and overall investment volume for Chemomab Therapeutics.
Keep exploring
The entities involved
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- Source Capital, Inc. filed required documents with the Securities and Exchange Commission regarding institutional ownership changes.
- The SEC is tracking 13F filings submitted by institutional investors, involving Omnicom Group.
- SEC filing tracks institutional investment in TOV.
- Robertson Stephens Wealth Management LLC filed with the SEC after buying a new stake in Welsbach Technology Metals Acquisition.
- Novo Nordisk filed required documents with the SEC regarding stock changes on October 22, 2026.